Fact.MR has recently added a new report to its vast online database. This research study is titled as “Peptide Based Metabolic Disorders Therapeutics Market Report” which presents an in-depth study about the production, consumption, market volume, revenue (million USD) and market share across different geographical regions.
Request For Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=187
There are several ongoing research activities and technological developments in accordance with medical research activities which focus on treatment of various ailments. Peptide therapeutics are used to treat several of these ailments, of which metabolic disorders are one type. Peptides possess good stability, efficacy, safety, and moreover, they are small in size, and hence can be easily synchronized. These advantages fuel the growth of the global peptide based metabolic disorders therapeutics market. To support the growth, factors such as technological advancements and increased funding in healthcare, and the impressive business growth of biotech and pharmaceutical companies, have spurred the adoption of the peptides used to treat metabolic disorders. Such disorders have risen, and this has called for a rapid development of therapies based on peptides to treat such disorders. North America is anticipated to show higher attractiveness in the global peptide based metabolic disorders therapeutics market.
5 Forecast Highlights on Global Peptide Based Metabolic Disorders Therapeutics Market
1) North America expected to grow at the highest CAGR to reflect a growth rate of 10.6% during the period of forecast as well as dominate the global market in terms of market share by revenue, as of 2017. It can be said that this trend would be followed, considering the technological developments, and the higher investments in the healthcare industry that this segment portrays, and retain its dominant position by the end of 2022, at least
2) Asia-Pacific excluding Japan (APEJ) region also anticipated to grow at a similar growth rate as of North America region, yet does not portray high market share by revenue. The market share by revenue of APEJ is less than one third than that of North America region and less than half of the market revenue share of the Europe region
3) Liraglutide segment by drug class is expected to grow at a robust rate during the period of forecast and dominates the market by drug class in terms of market share by revenue as of 2017. However, the growth rate of this segment is comparatively low than that of the other two segments by drug class
4) The others segment and the exenatide segment by drug class are poised to grow at a similar growth rate throughout the period of forecast, 2017 to 2022. However, the exenatide segment experiences a higher market share by revenue than the other segment. Both these segments are expected to gain BPS by the end of 2022, exenatide segment having an upper hand with respect to BPS aspect as well
5) Hospital pharmacies segment reflect higher market share by revenue and a well off growth rate during the period of forecast. But it is bound to lose BPS by the end of 2022. The retail pharmacies segment stands second as far as market share by revenue is concerned, and it has a higher growth rate than the hospital pharmacies segment. The online pharmacies segment is the fastest growing segment by distribution channel, and is expected to register a CAGR of 11.8% during the period of forecast. Yet, this segment has low market share by revenue as compared to the other two segments. It is also anticipated that the online pharmacies segment will gain a huge BPs by the end of 2022
North America Domination in the Peptide Based Metabolic Disorders Therapeutics
With respect to the global peptide based metabolic disorders therapeutics market, according to the market observation in 2016 and 2017, the region of North America is expected to dominate the global market in terms of higher market share. In terms of revenues, North America is poised to grow at a higher growth rate, registering a CAGR of 10.6% throughout the period of forecast of 2017 to 2022. This region is expected to show the highest market attractiveness index, and is the most lucrative region for the growth of the global peptide based metabolic disorders therapeutics market. Middle East and Africa (MEA) and Latin America regions will show slower growth rate as compared to North America, as well as a comparatively low market revenue share
APEJ Shows a Similar Growth Rate
The Asia-Pacific excluding Japan (APEJ) region had shown rapid growth in the past with respect to global peptide based metabolic disorders therapeutics market, and is poised to reflect a higher growth rate, as fast as North America. APEJ will register a CAGR of 10.5% during the forecast period. The main reasons for this kind of growth is the strict government regulations for the upcoming players, higher number of pharmaceutical companies, increased foreign direct investment and development of technologies. Moreover, the government encourages to increase the investment in the healthcare industry to discover and invent new methods & technologies to better the health of the patients and enhance treatment outcomes. Europe region, following APEJ region, also reflects itself as a positive platform for the growth of the global peptide based metabolic disorders therapeutics market.
Liraglutide Dominates the Drug Class Category
The liraglutide segment by drug class reflects a higher market share by revenue and dominates the global market by drug class. The market share of this segment is more than two and a half times than that of the exenatide segment as of 2017. However, it is anticipated that this segment will lose BPS by the end of 2022. The growth of liraglutide segment is slow as compared to the growth rates of the exenatide and others segments throughout the period of forecast.
Exenatide and Others Segments Have a Tie
The exenatide and others segments by drug class show similar growth rate and hence can be said to congruently move along during the period of forecast. However, the exenatide segment enjoys a higher market share than the others segment, more than three times than that of the others segment during 2017 and this trend is expected to run its course throughout the period of forecast. Both these segments are expected to show a gain in the BPS by the end of 2022.
Browse Full Report with TOC @ https://www.factmr.com/report/187/peptide-based-metabolic-disorders-therapeutics-market
Hospital Pharmacies Segment Shows Supremacy, Online Pharmacy Shows Growth
The hospital pharmacies segment by distribution channel reflect a higher market share by revenue and a higher growth rate throughout the period of forecast. However, the online pharmacies segment shows even higher growth rate as compared to hospital pharmacies segment, and is expected to register a CAGR of 11.8% during the period of forecast. But the market share of this segment is less; hospital pharmacies segment enjoys a market share more than three times than that of online pharmacies segment. The online pharmacies segment is expected to enjoy a gain in the BPS by the end of 2022. On the other hand, the retail pharmacies segment shows moderate growth rate, yet higher than that of the hospital pharmacies segment and a market share more than double than that of the online pharmacies segment as of 2017.
Competition Tracking
The report also profiles companies that are expected to remain active in the expansion of the global peptide based metabolic disorders therapeutics market through 2022, which include AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Novo Nordisk A/S, Merck & Co., Inc., Ipsen S.A, Eli Lilly and Company, CordenPharma International, and Bachem Holding AG.
Check Discount @ https://www.factmr.com/connectus/sample?flag=D&rep_id=187
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Healthcare market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/